MacroGenics (MGNX)
(Delayed Data from NSDQ)
$14.82 USD
+0.26 (1.79%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $14.81 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MGNX 14.82 +0.26(1.79%)
Will MGNX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MGNX
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
MGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates
MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why
Other News for MGNX
Masters In Trading - Saturday, April 27
Snap upgraded, Apple downgraded: Wall Street's top analyst calls
B. Riley starts MacroGenics at Buy on 'de-risked' lead asset
MacroGenics initiated with bullish view at B. Riley
Buy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial Results